IDENIX PHARMACEUTICALS INC
IDIX
IDIX was delisted on the 5th of August, 2014.
96 hedge funds and large institutions have $696M invested in IDENIX PHARMACEUTICALS INC in 2014 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 31 increasing their positions, 24 reducing their positions, and 12 closing their positions.
159% more call options, than puts
Call options by funds: $9.08M | Put options by funds: $3.51M
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
29% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 24
11% more capital invested
Capital invested by funds: $628M → $696M (+$67.8M)
9% more funds holding
Funds holding: 88 → 96 (+8)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
+$115M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.87M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$4.89M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.64M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$4.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$28.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.42M |
| 3 |
BM
Bridger Management
New York
|
-$5.23M |
| 4 |
FAM
Fred Alger Management
New York
|
-$3.51M |
| 5 |
D.E. Shaw & Co
New York
|
-$3.35M |
IDIX Hedge Fund Activity: Q1 2014 in Review
96 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in IDENIX PHARMACEUTICALS INC (IDIX) for Q1 2014, worth a combined $696M — up 11% from $628M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new IDIX positions and 12 closed out — a net gain of 8 holders — while 31 added to existing stakes and 24 trimmed.
The largest buyer was Baupost Group, adding an estimated $115M. The largest seller was Bain Capital Public Equity Management, cutting an estimated $28.7M.
- 96 institutional investors held IDENIX PHARMACEUTICALS INC (IDIX) as of Q1 2014, up from 88 in Q4 2013.
- Funds reported $696M of IDENIX PHARMACEUTICALS INC stock for Q1 2014, up 11% quarter-over-quarter.
- 20 funds opened new IDENIX PHARMACEUTICALS INC positions in Q1 2014 and 12 closed out, a net change of +8 holders.
- The largest IDENIX PHARMACEUTICALS INC buyer in Q1 2014 was Baupost Group, an estimated $115M added.
- The largest IDENIX PHARMACEUTICALS INC seller in Q1 2014 was Bain Capital Public Equity Management, an estimated $28.7M sold.
Based on aggregated 13F filings for Q1 2014.